NCT03081247View on ClinicalTrials.gov

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 16, 2018

Primary Completion Date

December 7, 2018

Study Completion Date

December 7, 2018

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

BGF 320/14.4/9.6 µg MDI

Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)

DRUG

BFF 320/9.6 µg

Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY